Igcasan, Mary Jane .
HRN: 22-79-16 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
08/18/2023
CEFUROXIME 500MG (TAB)
08/18/2023
08/24/2023
ORAL
500mg
BID
RMLE, With Repair
Checking Final Appropriateness
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes